Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn’s Disease: A Post Hoc Analysis of GEMINI 2 and 3.

Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn’s Disease: A Post Hoc Analysis of GEMINI 2 and 3. Inflamm Bowel Dis. 2019 Jan 04;: Authors: Sands BE, Van Assche G, Tudor D, Akhundova-Unadkat G, Curtis RI, Tan T Abstract Background: Combined therapy with vedolizumab and corticosteroids may improve clinical response or remission in Crohn’s disease. The aim of this study is to assess efficacy and safety/tolerability of vedolizumab plus stable doses of corticosteroids at baseline during induction therapy in moderately to severely active Crohn’s disease. Methods: A post…

Read More

Postoperative Steroid Taper Is Associated With Pelvic Sepsis After Ileal Pouch-anal Anastomosis.

Postoperative Steroid Taper Is Associated With Pelvic Sepsis After Ileal Pouch-anal Anastomosis. Inflamm Bowel Dis. 2018 Dec 28;: Authors: Ritter KA, Burke JP, Stocchi L, Aiello A, Holubar S, Ashburn JH, Lipman JM, Shawki S, Hull T Abstract Objective: We hypothesized that postoperative oral steroid taper after ileal pouch-anal anastomosis for inflammatory bowel disease would not be associated with pelvic septic complications. Background: Recent data has emphasized the possible association between biologic medication use and pelvic sepsis following ileal pouch-anal anastomosis. Limited contemporary data exist examining the effects of steroid…

Read More

Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohn’s Disease.

Related Articles Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohn’s Disease. Inflamm Bowel Dis. 2018 Dec 09;: Authors: Scott FI, Johnson FR, Bewtra M, Brensinger CM, Roy JA, Reed SD, Osterman MT, Mamtani R, Chen L, Yun H, Xie F, Curtis JR, Lewis JD Abstract Background: Corticosteroids (CS) and anti-TNF drugs are used to treat Crohn’s disease (CD). In this study, we assessed the net health benefit of initiating anti-TNF therapy relative to additional CS use in CD using a novel combination of a…

Read More

Mucosal healing and bacterial composition in response to enteral nutrition versus steroid based induction therapy – a randomized prospective clinical trial in children with Crohn’s disease.

Related Articles Mucosal healing and bacterial composition in response to enteral nutrition versus steroid based induction therapy – a randomized prospective clinical trial in children with Crohn’s disease. J Crohns Colitis. 2018 Dec 12;: Authors: Pigneur B, Lepage P, Mondot S, Schmitz J, Goulet O, Doré J, Ruemmele FM Abstract Exclusive Enteral Nutrition (EEN) is as efficacious as corticosteroids (CS) to induce remission in Crohn’s disease (CD), without their adverse effects. EEN seems to be more efficient than steroids to induce mucosal healing, but the underlying molecular mechanisms are only…

Read More

Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids.

Related Articles Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids. Aliment Pharmacol Ther. 2018 Nov 14;: Authors: Noureldin M, Higgins PDR, Govani SM, Cohen-Mekelburg S, Kenney BC, Stidham RW, Waljee JF, Waljee AK Abstract BACKGROUND: Opioids are commonly prescribed to manage pain associated with inflammatory bowel disease (IBD). It is unknown what percentage of patients develop new persistent opioid use following a steroid-treated IBD flare. AIM: To identify the incidence and the predictors of new persistent opioid use following an IBD…

Read More

ANP32E, a protein involved in steroid-refractoriness in ulcerative colitis, identified by a systems biology approach.

ANP32E, a protein involved in steroid-refractoriness in ulcerative colitis, identified by a systems biology approach. J Crohns Colitis. 2018 Oct 17;: Authors: Lorén V, Garcia-Jaraquemada A, Naves JE, Carmona X, Mañosa M, Aransay AM, Lavin JL, Sánchez I, Cabré E, Manyé J, Domènech E Abstract Background and aims: Steroid-refractoriness is a common and unpredictable phenomenon in ulcerative colitis (UC), but there are no conclusive studies on the molecular functions involved. We aimed to assess in depth the mechanism of action related to steroid failure by integrating transcriptomic data from UC…

Read More

Smoking Status at Diagnosis and Subsequent Smoking Cessation: Associations With Corticosteroid Use and Intestinal Resection in Crohn’s Disease.

Related Articles Smoking Status at Diagnosis and Subsequent Smoking Cessation: Associations With Corticosteroid Use and Intestinal Resection in Crohn’s Disease. Am J Gastroenterol. 2018 Oct 15;: Authors: Alexakis C, Saxena S, Chhaya V, Cecil E, Majeed A, Pollok R Abstract BACKGROUND: The impact of smoking at diagnosis and subsequent smoking cessation on clinical outcomes in Crohn’s disease (CD) has not been evaluated in a population-based cohort. METHODS: Using a nationally representative clinical research database, we identified incident cases of CD between 2005 and 2014. We compared the following outcomes: overall…

Read More

Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection.

Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection. Inflamm Bowel Dis. 2018 Sep 26;: Authors: Solanky D, Pardi DS, Loftus EV, Khanna S Abstract Background: Inflammatory bowel disease (IBD) is an independent risk factor for Clostridium difficile infection (CDI), and CDI often precipitates IBD exacerbation. Because CDI cannot be distinguished clinically from an IBD exacerbation, management is difficult. We aimed to assess factors associated with adverse outcomes in IBD with CDI, including the role of escalating or de-escalating IBD therapy…

Read More

Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn’s Disease: A Bayesian Network Meta-analysis: Republished.

Related Articles Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn’s Disease: A Bayesian Network Meta-analysis: Republished. Inflamm Bowel Dis. 2017 May 01;23(5):E26-E37 Authors: Coward S, Kuenzig ME, Hazlewood G, Clement F, McBrien K, Holmes R, Panaccione R, Ghosh S, Seow CH, Rezaie A, Kaplan GG Abstract Background: Induction treatment of mild-to-moderate Crohn’s disease is controversial. Purpose: To compare the induction of remission between different doses of mesalamine, sulfasalazine, corticosteroids, and budesonide for active Crohn’s disease. Data sources: We identified randomized controlled trials from…

Read More

Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn’s Disease: A Bayesian Network Meta-Analysis: ERRATUM.

Related Articles Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn’s Disease: A Bayesian Network Meta-Analysis: ERRATUM. Inflamm Bowel Dis. 2017 May 01;23(5):E25 Authors: PMID: 30052984 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30052984?dopt=Abstract

Read More
<< Go Back